Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease.
Level 5 - mechanism / opinion, no new human data
Animal study (rat model)
PubMed 26484876 · doi:10.1371/journal.pone.0140880
What was done
Rats with unilateral adeno-associated virus (AAV)-mediated overexpression of human α-synuclein in the substantia nigra were treated with daily bilateral cranial exposure to 808-nm near-infrared light (photobiomodulation, PBM) for 28 consecutive days. Outcomes assessed included motor function via the cylinder test, dopaminergic neuronal loss in the substantia nigra, and dopaminergic fiber integrity in the ipsilateral striatum, with follow-up evaluated up to 6 weeks after treatment cessation.
What was found
The abstract reports no numerical values. It states qualitatively that 28 days of 808-nm light exposure alleviated α-synuclein-induced motor impairment on the cylinder test, significantly reduced dopaminergic neuron loss in the substantia nigra, preserved striatal dopaminergic fibers, and sustained these benefits for at least 6 weeks after discontinuing treatment.
Why it matters
These findings suggest that non-invasive near-infrared photobiomodulation may provide neuroprotection and long-lasting functional improvement against α-synuclein-induced pathology in preclinical models of Parkinson's disease.
Limits
This is an animal study in an AAV-induced rat model, which cannot establish clinical efficacy or safety in humans. The abstract does not report the sample size (n), light dosimetry parameters (power density/fluence), quantitative effect sizes, or confidence intervals.
Cited by
- supports Photobiomodulation reduces and reverses misfolding and accumulation of alpha-synuclein, tau protein, and beta-amyloid in neurodegenerative disease models.